Randomized, double-blind comparison of venlafaxine and sertraline in outpatients with major depressive disorder

Journal of Clinical Psychiatry

Volumn 61, Issue 2, 2000, Pages 95-100

  Mehtonen, Olli Pekka ^a,c   Søgaard, Jesper ^d   Roponen, Pekka ^d   Behnke, Kirsten ^b  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b FREDERIKSBERG HOSPITAL   (Denmark)

^c Psykoforum   (Finland)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

SERTRALINE; VENLAFAXINE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; MALE; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION;

EID: 0034102113     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v61n0204     Document Type: Article

References (25)

1. Clerc GE, Ruimy P, Verdeau-Pailles. A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. Int Clin Psychopharmacol 1994;9:139-143
2. Costa e Silva J. Randomized, double-blind comparison of venlafaxine and fluoxetine in outpatients with major depression. J Clin Psychiatry 1998; 59:352-357
3. Dierick M, Martin A, Ravizza L, et al. A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients. Prog Neuropsychopharmacol Biol Psychiatr 1996;20:57-71
4. Poirier M-F, Boyer P. Venlafaxine and paroxetine in treatment-resistant depression: double-blind, randomised comparison. Br J Psychiatry 1999; 175:12-16
5. McPartlin GM, Reynolds A, Anderson C, et al. A comparison of once-daily venlafaxine XR and paroxetine in depressed outpatients treated in general practice. Prim Care Psychiatry 1998;4:127-132
6. Smeraldi E, Rizzo F. Double-blind, randomized study of venlafaxine, clomipramine, and trazodone in geriatric patients with major depression. Prim Care Psychiatry 1998;4:189-195
7. Tylee A, Beaumont G, Bowden M, et al. A double-blind, randomised, 12-week comparison study of the safety and efficacy of venlafaxine and fluoxetine in moderate to severe depression in general practice. Prim Care Psychiatry 1997;3:51-58
8. Mendels J. The acute and long-term treatment of major depression. Int Clin Psychopharmacol 1992;7(suppl 2):21-30
9. Montgomery S. Serotonin, sertraline and depression. J Psychopharmacol 1995;9(suppl):179-184
10. Preskorn SH, Lane RM. Sertraline 50 mg: optimal dose in the treatment of depression. Int Clin Psychopharmacol 1995;10:129-141
11. Khan A, Upton GV, Rudolph RL, et al. The use of venlafaxine in the treatment of major depression and major depression associated with anxiety: a dose-response study. J Clin Psychopharmacol 1998;18:19-25
12. Rudolph RL, Fahre LF, Feighner JP, et al. Randomized, placebo-controlled, dose-response trial of venlafaxine hydrochloride in the treatment of major depression. J Clin Psychiatry 1998;59:116-122
13. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967;6:278-296
14. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-389
15. Guy W. ECDEU Assessment Manual for Psychopharmacology, Revised. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976
16. Lingjærde O, Ahlfors UG, Bech P, et al. The UKU side-effect rating scale. Acta Psychiatr Scand 1987;76(suppl 334):1-100
17. Silverstone PH, Ravindran A, for the Venlafaxine XR 360 Study Group. Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. J Clin Psychiatry 1999;60: 22-28
18. Rudolph RL, Feiger AD. A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of major depression. J Affect Disord. In press
19. Frank E, Prien RF, Jarrett RB, et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder: remission, recovery, relapse and recurrence. Arch Gen Psychiatry 1991;48:451-455
20. Prien RF, Carpenter LL, Kupfer DJ. The definition and operational criteria for treatment outcome of major depressive disorder: a review of the current research literature. Arch Gen Psychiatry 1991;48:796-800
21. Tignol J, Stoker MJ, Dunbar GC. Paroxetine in the treatment of melancholic and severe depression. Int Clin Psychopharmacol 1992;7:91-94
22. Feighner JP, Cohn JB, Fabre LF, et al. A study comparing paroxetine placebo and imipramine in depressed patients. J Affect Disord 1993;28: 71-79
23. Dubini A, Bosc M, Polin V. Noradrenaline-selective versus serotonin-selective antidepressant therapy: differential effects on social functioning. J Psychopharmacol 1997;11(suppl):S17-S25
24. Ekselius L, von Knorring L, Eberhard G. A double-blind, multicenter trial comparing sertraline and citalopram in patients with major depression treated in general practice. Int Clin Psychopharmacol 1997;12:323-331
25. Muth EA, Haskins JT, Moyer JA, et al. Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative. Biochem Pharmacol 1986;35:4493-4497